What is the main business of Meritro?

The main business activity of Meritro focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on May 27, 2024.

Where is the headquarters located?

The headquarters is located at: Gospodarcza 26, 20-213 Lublin.

Who is on the management board?

The management board consists of: Paweł Burzyński (President of the Management Board) and Jarosław Walczak (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from May 27, 2024 to December 31, 2024.

How much revenue was generated?

In 2024, the company generated total revenue of $7,891.

No, the company recorded a net loss of $2,144 in 2024.

Meritrosp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2024-05-27

Share capital

5 000,00 PLN

Activity description

Meritro is a company that offers OncoVetCure, a diagnostic platform for personalized veterinary oncology. This platform utilizes ex vivo cell cultures to assess the sensitivity of cancer cells to various drugs, enabling veterinarians to customize cancer treatments for dogs. The service aims to enhance treatment effectiveness and improve the chances of recovery for canine patients.

Registered address

Gospodarcza 26, 20-213 Lublin, Poland

Website

meritro.com

Electronic delivery address

AE:PL-70076-74661-JVHFF-23

Financials

Revenue history

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 0.05MedianUSD 38.31kAverageUSD 2.31m

Net profit

This companyUSD -2.87kMedianUSD -1.50kAverageUSD -84.98k

Operating costs

This companyUSD 2.87kMedianUSD 56.25kAverageUSD 2.29m

Assets

This companyUSD 1.03kMedianUSD 116.77kAverageUSD 2.72m

Industry

Bank accounts

Registered as a VAT taxpayer on 2025-01-20. Active

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

Grant date	Purpose	Gross amount	Granting body
Jun 12, 2024	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$13,958$13,958	Polska Fundacja Ośrodków Wspomagania Rozwoju Gospodarczego Oic Poland z Siedzibą w Lublinie

Tenders

No recorded participation in tenders.

Authorized Representatives

Paweł Burzyński — President of the Management Board

Jarosław Walczak — President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Aleksandra Burzyńska (45)	40	$540.25	22.2222%
Michał Komorowski (46)	40	$540.25	22.2222%
Jarosław Walczak (41)	100	$1,350.62	55.5556%

Beneficial owners

Person	Rights
Jarosław Walczak (41)	Shareholder of a limited liability company, 5000.0 PLN

Competitors

	Name	Revenue	Website
	ImmunotronicsP.S.A.	$0.16	immunotronics.net

FAQ

Last updated: 2026-08-02